Need for streamlined use of DPP-4 inhibitors in the treatment of type 2 diabetes

Regulatory agencies request an assessment of cardiovascular safety for all “new” oral anti-diabetic drugs in order to avoid possible negative effects on cardiovascular events. Dipeptidyl peptidase 4 inhibitors have emerged as a new therapeutic alternative for the treatment of type 2 diabetes mellitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Cristiana, Rosano, Giuseppe M. C., Prasad, Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818902/
https://www.ncbi.nlm.nih.gov/pubmed/27039303
http://dx.doi.org/10.1186/s12933-016-0379-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818902/
https://www.ncbi.nlm.nih.gov/pubmed/27039303
http://dx.doi.org/10.1186/s12933-016-0379-4

Ejemplares similares